DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 148 filers reported holding DENALI THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | – | 0 | – | 0.00% | – |
| Q2 2023 | $0 | – | 0 | – | 0.00% | – |
| Q1 2023 | $0 | – | 0 | – | 0.00% | – |
| Q4 2022 | $0 | – | 0 | – | 0.00% | – |
| Q3 2022 | $0 | – | 0 | – | 0.00% | – |
| Q2 2022 | $0 | – | 0 | – | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q4 2021 | $464,000 | – | 10,402 | – | 0.00% | – |
| Q3 2021 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q2 2021 | $566,000 | +37.4% | 7,210 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $412,000 | – | 7,210 | – | 0.00% | – |
| Q4 2020 | $0 | – | 0 | – | 0.00% | – |
| Q3 2020 | $0 | – | 0 | – | 0.00% | – |
| Q2 2020 | $0 | – | 0 | – | 0.00% | – |
| Q1 2020 | $0 | – | 0 | – | 0.00% | – |
| Q4 2019 | $0 | – | 0 | – | 0.00% | – |
| Q3 2019 | $0 | – | 0 | – | 0.00% | – |
| Q2 2019 | $0 | – | 0 | – | 0.00% | – |
| Q1 2019 | $0 | – | 0 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $219,569,000 | 28.65% |
| ARCH Venture Management, LLC | 5,168,749 | $152,116,000 | 18.54% |
| Casdin Capital, LLC | 1,500,000 | $44,145,000 | 3.73% |
| Flagship Pioneering Inc. | 2,619,968 | $77,106,000 | 2.90% |
| Yiheng Capital Management, L.P. | 1,014,684 | $29,862,000 | 1.71% |
| SECTORAL ASSET MANAGEMENT INC | 202,100 | $5,948,000 | 1.20% |
| GILDER GAGNON HOWE & CO LLC | 1,956,820 | $57,589,000 | 1.03% |
| Artal Group S.A. | 600,000 | $17,658,000 | 0.94% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $158,024,002 | 0.87% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $283,000 | 0.69% |